Showing posts with label hypertension. Show all posts
Showing posts with label hypertension. Show all posts

Tuesday, February 6, 2024

Amlodipine: Discovery and Development

Amlodipine, a widely used medication available in generic form, is also distributed under brand names like Norvasc and Katerzia. This versatility underscores its importance in treating various cardiovascular conditions. Generic drugs, including amlodipine, are formulated to contain the same active ingredients and produce similar therapeutic effects as their branded counterparts, ensuring affordability and accessibility for patients worldwide.

Belonging to the category of oral dihydropyridine calcium channel blockers, amlodipine's development traces back to a comprehensive pharmacological study initiated in 1964 in the laboratory of renowned scientist Dr. Paul Godfraind. Pfizer, a leading pharmaceutical company, spearheaded the discovery of amlodipine and successfully secured its patent in 1982 (US patent 4,572,909), marking a significant milestone in cardiovascular medicine.

In the initial stages of drug development, Pfizer explored the feasibility of using a maleate salt form of amlodipine. However, due to inherent challenges related to instability and manufacturing, this approach was discontinued. Undeterred, Pfizer's research team diligently pursued alternative formulations, eventually culminating in the development of the besylate salt form, commercially known as Norvasc, which debuted in 1990. The decision to focus on besylate salt was vindicated by its superior attributes, including enhanced solubility, stability, non-hygroscopicity, and ease of manufacturing, as highlighted in the patent filed in 1986 (US patent 4,879,303). This breakthrough paved the way for amlodipine's widespread adoption and regulatory approval by the FDA in 1987.

Since its approval for medical use in 1990, amlodipine has garnered recognition as an essential medication, earning a coveted spot on the World Health Organization's Essential Medicines List. Its inclusion underscores its clinical efficacy and public health significance. Remarkably, amlodipine's impact extends beyond regulatory recognition, evident in its remarkable prescription statistics. In 2021 alone, amlodipine emerged as the fifth most prescribed medication in the United States, with healthcare professionals issuing over 73 million prescriptions, reaffirming its pivotal role in managing cardiovascular disorders and improving patient outcomes.
Amlodipine: Discovery and Development

Saturday, August 23, 2014

Discovery of atenolol

Atenolol is a Beta-1 cardio-selective adreno-receptor blocking agent discovered and developed by ICI in 1976.

Beta blockers are among one of the safest and most effective anti-hypertensive drugs available.

Practolol was the first cardio-selective beta -blocker, also discovered and developed by ICI in the mid-1960s, but ICI withdrew it in 1975 after it was found to be toxic.

In 1964 ICI eventually produced the drug propranolol, which possessed a better efficacy and safety profile. Propranolol is now widely used in the management of angina, hypertension, arrhythmia, and migraine headache.

Two additional beta-blockers, Atenolol and Practolol, were later discovered.

Atenolol was launched in the market under the trade name Tenormin in 1976, and became the best-selling Beta-blocker in the world in the 1980s and 1990s.
Discovery of atenolol

The most popular articles

Selected Articles